Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Disease × lortalamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Magnetic Resonance Spectroscopy 3 Prednisone 2 Positron-Emission Tomography 2 Lenalidomide 2 Injections 2 Dexamethasone 2 Cyclophosphamide 2 technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1 obinutuzumab 1 lortalamine 1 fluciclovine F-18 1 Vindesine 1 Vincristine 1 Transplantation, Autologous 1 Thalidomide 1 Rituximab 1 Mitomycin 1 Melphalan 1 Doxorubicin 1 Diagnosis 1 Bleomycin 1 3-Iodobenzylguanidine 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡